Pyoderma gangrenosum
diseaseOn this page
Summary
Pyoderma gangrenosum (MONDO:0018824) is a disease and 32 clinical trials. Top therapeutic interventions include cravacitinib, oxygen, and spesolimab. A subtype of pyoderma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Worldwide) [Orphanet-validated]
- Phenotypes (HPO): 15
- Clinical trials: 32
Clinical features
Epidemiology
Prevalence records
5 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.74 | Worldwide | Validated |
| Annual incidence | 1-9 / 100 000 | 1 | United States | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.91 | United Kingdom | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.33 | Spain | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.517 | Italy | Validated |
Signs & symptoms
Clinical features (HPO)
15 HPO clinical features (Orphanet curated; top 15 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001945 | Fever | Very frequent (80-99%) |
| HP:0002829 | Arthralgia | Very frequent (80-99%) |
| HP:0003326 | Myalgia | Very frequent (80-99%) |
| HP:0100614 | Myositis | Very frequent (80-99%) |
| HP:0200034 | Papule | Very frequent (80-99%) |
| HP:0200042 | Skin ulcer | Very frequent (80-99%) |
| HP:0001075 | Atrophic scars | Frequent (30-79%) |
| HP:0001370 | Rheumatoid arthritis | Frequent (30-79%) |
| HP:0002037 | Inflammation of the large intestine | Frequent (30-79%) |
| HP:0002863 | Myelodysplasia | Frequent (30-79%) |
| HP:0010702 | Increased circulating antibody level | Frequent (30-79%) |
| HP:0012324 | Myeloid leukemia | Frequent (30-79%) |
| HP:0200039 | Pustule | Frequent (30-79%) |
| HP:0008066 | Abnormal blistering of the skin | Occasional (5-29%) |
| HP:0200037 | Skin vesicle | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pyoderma gangrenosum |
| Mondo ID | MONDO:0018824 |
| MeSH | D017511 |
| Orphanet | 48104 |
| DOID | DOID:8553 |
| ICD-10-CM | L88 |
| ICD-11 | 2120746218 |
| SNOMED CT | 74578003 |
| UMLS | C0085652 |
| MedGen | 43224 |
| GARD | 0007510 |
| MedDRA | 10037635 |
| NORD | 1638 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of pyoderma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › pyoderma › pyoderma gangrenosum
Related subtypes (4): cutaneous diphtheria, carbuncle, erythrasma, impetigo
Subtypes (4): classic pyoderma gangrenosum, pustular pyoderma gangrenosum, bullous pyoderma gangrenosum, vegetative pyoderma gangrenosum
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 32.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 14 |
| PHASE3 | 7 |
| Not specified | 6 |
| PHASE4 | 2 |
| EARLY_PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07240649 | PHASE4 | NOT_YET_RECRUITING | Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications |
| NCT05120726 | PHASE4 | TERMINATED | A Novel Therapeutic Treatment of Pyoderma Gangrenosum |
| NCT06624670 | PHASE3 | RECRUITING | A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum |
| NCT02315417 | PHASE3 | TERMINATED | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum |
| NCT02318914 | PHASE3 | TERMINATED | A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum |
| NCT02326740 | PHASE3 | TERMINATED | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum |
| NCT03311464 | PHASE3 | COMPLETED | A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan |
| NCT05343754 | PHASE3 | TERMINATED | Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum |
| NCT05964413 | PHASE3 | TERMINATED | Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum |
| NCT06563323 | PHASE2 | RECRUITING | Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) |
| NCT07337564 | PHASE2 | NOT_YET_RECRUITING | A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum |
| NCT07444684 | PHASE2 | NOT_YET_RECRUITING | A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum |
| NCT00690846 | PHASE2 | WITHDRAWN | Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum |
| NCT00730717 | PHASE2 | WITHDRAWN | Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum |
| NCT01302795 | PHASE2 | COMPLETED | Canakinumab for Pyoderma Gangrenosum |
| NCT01882504 | PHASE2 | COMPLETED | Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum |
| NCT01965613 | PHASE2 | COMPLETED | A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum |
| NCT02733094 | PHASE1/PHASE2 | COMPLETED | Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum |
| NCT03072953 | PHASE2 | TERMINATED | Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum |
| NCT03137160 | PHASE2 | COMPLETED | An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum |
| NCT03971643 | PHASE2 | COMPLETED | Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum |
| NCT04274166 | PHASE2 | WITHDRAWN | Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum |
| NCT04901325 | PHASE2 | COMPLETED | Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) |
| NCT06092216 | PHASE2 | TERMINATED | Spesolimab in Pyoderma Gangrenosum |
| NCT04895566 | EARLY_PHASE1 | COMPLETED | Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma |
| NCT05821374 | EARLY_PHASE1 | WITHDRAWN | Deucravacitinib in PG |
| NCT00791557 | Not specified | COMPLETED | Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease |
| NCT01952275 | Not specified | UNKNOWN | Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases |
| NCT03636737 | Not specified | UNKNOWN | Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum |
| NCT04750213 | Not specified | COMPLETED | A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG) |
| NCT04792957 | Not specified | UNKNOWN | JAK-STAT Signaling Pathway in Pyoderma Gangrenosum |
| NCT05984654 | Not specified | WITHDRAWN | Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CRAVACITINIB | 4 | 3 |
| OXYGEN | 4 | 2 |
| SPESOLIMAB | 4 | 2 |
| BARICITINIB | 4 | 1 |
| CANAKINUMAB | 4 | 1 |
| ETRASIMOD | 4 | 1 |
| GUSELKUMAB | 4 | 1 |
| IXEKIZUMAB | 4 | 1 |
| GEVOKIZUMAB | 3 | 4 |
| VILOBELIMAB | 3 | 2 |
| BERMEKIMAB | 3 | 1 |
| CHEMBL5427854 | 0 | 1 |